Gsk (GLAXF) Operating Expenses (2009 - 2026)

Gsk's Operating Expenses history runs 18 years deep, the most recent figure standing at -$5.1 billion for Q1 2026.

• In Q1 2026, Operating Expenses fell 15.5% year-over-year to -$5.1 billion; the TTM figure through Mar 2026 stood at -$38.1 billion (up 1.35% YoY), while the FY2025 annual figure was $21.9 billion, down 1.61% from the prior year.
• Operating Expenses was -$5.1 billion for Q1 2026 at Gsk, up from -$22.1 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of -$3.9 billion in Q1 2022 to a low of -$22.4 billion in Q4 2024.
• Historically, Operating Expenses has averaged -$8.4 billion across 5 years, with a median of -$5.0 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses slumped 42.79% in 2022, then increased 22.43% in 2025.
• A 5-year view of Operating Expenses shows it stood at -$16.3 billion in 2022, then declined by 19.16% to -$19.4 billion in 2023, then declined by 15.39% to -$22.4 billion in 2024, then gained by 1.14% to -$22.1 billion in 2025, then jumped by 76.75% to -$5.1 billion in 2026.
• The last three Operating Expenses figures came in at -$5.1 billion (Q1 2026), -$22.1 billion (Q4 2025), and -$5.3 billion (Q3 2025), per Business Quant data.